Proton Pump Inhibitors Use and Risk of Inflammatory Bowel Diseases: a Meta-analysis of Observational Studies

Overview

Journal Med Pharm Rep

Specialty General Medicine

Date 2022 Dec 12

PMID 36506599

Authors

Sanjana Aditya Shastri

Raveena Kantamneni

Muhammed Rashid

Viji Pulikkel Chandran

Ramadugula Suhita

Izwath Begum

Sreedharan Nair

Girish Thunga

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Proton Pump Inhibitors (PPIs) reduce gastric acid production and they are indicated for myriad gastrointestinal conditions. Prolonged use of PPI has been linked to the risk of inflammatory bowel disease (IBD) though this fact is not well established. We aimed to conduct a systematic review and meta-analysis to estimate the risk of IBD occurrence with PPI use.

Methodology: The databases such as PubMed, Scopus, and Cochrane Library were accessed from inception to December 2020. Additionally, the bibliographic search and a random search in Google, Google Scholar, and ResearchGate were performed to find additional sources. The observational studies estimating the risk of IBD following the use of PPI, published in the English language were considered for this review. The methodological quality of included studies was assessed using the Modified Downs and Black checklist.

Results: Eight out of 2038 studies with 157,758 participants were included in this meta-analysis. A significantly higher risk of IBD (adjusted odds ratio [aOR] 2.43; 95% Confidence Interval [CI] 1.18-5.02; P=0.02; n=6) was observed in participants taking PPIs for any indication. Moreover, a significant association was observed between PPI exposure on the different types of IBD such as ulcerative colitis and Crohn's disease together (aOR: 3.60; 95% CI: 1.10-11.74), collagenous colitis (OR: 4.73; 95% CI: 1.99-11.22) and lymphocytic Colitis (OR: 3.77; 95% CI: 2.91-4.87), but not with ulcerative colitis (P=0.47) and microscopic colitis (P=0.07) alone. Similarly, a significant association was observed among Europeans (aOR: 3.98; 95% CI: 2.36-6.71), but not with North American (aOR: 0.48; 95% CI: 0.01-26.71) studies. Overall the study quality was good.

Conclusion: The current evidence indicates that exposure to PPI is significantly associated with increased risk of IBD. Further, adequately powered studies from various parts of the world are needed for better quantification and generalizability of our findings.

Prospero Protocol Registration Number: CRD42020209674.

Citing Articles

Risk factors for inflammatory bowel disease: an umbrella review.

Wu T, Cheng H, Zhuang J, Liu X, Ouyang Z, Qian R Front Cell Infect Microbiol. 2025; 14:1410506.

PMID: 39926114 PMC: 11802543. DOI: 10.3389/fcimb.2024.1410506.

Critical analysis of the effects of proton pump inhibitors on inflammatory bowel disease: An updated review.

Goyal O, Goyal M World J Gastroenterol. 2024; 30(37):4160-4162.

PMID: 39474398 PMC: 11514535. DOI: 10.3748/wjg.v30.i37.4160.

Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance.

Zhang X, Li Q, Xia S, He Y, Liu Y, Yang J Biomedicines. 2024; 12(10).

PMID: 39457584 PMC: 11504961. DOI: 10.3390/biomedicines12102271.

Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.

Migliorisi G, Mastrorocco E, Dal Buono A, Gabbiadini R, Pellegatta G, Spaggiari P J Clin Med. 2024; 13(14).

PMID: 39064159 PMC: 11278413. DOI: 10.3390/jcm13144119.

Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR.

Prabhoo R, Pai U, Wadhwa A, Pillai B, Dsouza C, Wadhawan M Euroasian J Hepatogastroenterol. 2024; 14(1):99-119.

PMID: 39022200 PMC: 11249898. DOI: 10.5005/jp-journals-10018-1430.

References

Verhaegh B, de Vries F, Masclee A, Keshavarzian A, de Boer A, Souverein P . High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016; 43(9):1004-13. DOI: 10.1111/apt.13583. View

Khalili H, Burke K, Roelstraete B, Sachs M, Olen O, Ludvigsson J . Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study. Gastroenterology. 2020; 158(6):1574-1583.e2. DOI: 10.1053/j.gastro.2019.12.028. View

Schwartz N, Hutfless S, Herrinton L, Amsden L, Fevrier H, Giefer M . Proton Pump Inhibitors, H Blocker Use, and Risk of Inflammatory Bowel Disease in Children. J Pediatr Pharmacol Ther. 2019; 24(6):489-496. PMC: 6836698. DOI: 10.5863/1551-6776-24.6.489. View

Xia B, Crusius J, Meuwissen S, Pea A . Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. World J Gastroenterol. 2002; 4(5):446-458. PMC: 4767749. DOI: 10.3748/wjg.v4.i5.446. View

Rashid M, Kashyap A, Undela K . Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol. 2019; 58(9):1014-1022. DOI: 10.1111/ijd.14411. View

Shastri S, Kantamneni R, Rashid M, Chandran V, Suhita R, Begum I . Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies. Med Pharm Rep. 2022; 95(4):357-369. PMC: 9694755. DOI: 10.15386/mpr-2259. View

Keszthelyi D, Jansen S, Schouten G, de Kort S, Scholtes B, Engels L . Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010; 32(9):1124-8. DOI: 10.1111/j.1365-2036.2010.04453.x. View

Pascua M, Kedia P, Weiner M, Holmes J, Ellenberg J, Lewis J . Microscopic colitis and Medication Use. Clin Med Insights Gastroenterol. 2010; 2010(3):11-19. PMC: 2903747. DOI: 10.4137/cgast.s4469. View

Carrasco A, Fernandez-Banares F . Th1 Pathway: The Missing Link Between Inflammatory Bowel Disease and Microscopic Colitis?. Dig Dis Sci. 2017; 62(10):2609-2611. DOI: 10.1007/s10620-017-4692-x. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

11.

Rashid M, Shamshavali K, Chhabra M . Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. Curr Clin Pharmacol. 2019; 14(2):108-115. PMC: 7040499. DOI: 10.2174/1574884714666190112151202. View

12.

Masclee G, Coloma P, Kuipers E, Sturkenboom M . Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015; 110(5):749-59. DOI: 10.1038/ajg.2015.119. View

13.

Downs S, Black N . The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52(6):377-84. PMC: 1756728. DOI: 10.1136/jech.52.6.377. View

14.

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H . Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 7:113-20. PMC: 4106026. DOI: 10.2147/JIR.S65979. View

15.

Fernandez-Banares F, de Sousa M, Salas A, Beltran B, Piqueras M, Iglesias E . Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013; 19(2):411-7. DOI: 10.1002/ibd.23009. View

16.

Burgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke J . Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002; 123(2):433-43. DOI: 10.1053/gast.2002.34784. View

17.

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

18.

Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B . Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol. 2019; 25(22):2706-2719. PMC: 6580352. DOI: 10.3748/wjg.v25.i22.2706. View

19.

Shah R, Richardson P, Yu H, Kramer J, Hou J . Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Digestion. 2017; 95(3):188-193. DOI: 10.1159/000455008. View

20.

Reinink A . Do Acid-Suppressing Medications in Inflammatory Bowel Disease Increase Risk for Flare?. Digestion. 2017; 95(3):186-187. DOI: 10.1159/000464283. View